albumin - publications

Predict more albumin - ligand interactions now!

1. Int J Pharm. 2012 Apr 15. [Epub ahead of print]

The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin
nanoparticles in 4T1 tumor-bearing Balb/c mice.

Taheri A, Dinarvand R, Ahadi F, Khorramizadeh MR, Atyabi F.

Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical
Sciences, Tehran, Iran; Department of Pharmaceutics, Faculty of Pharmacy, Zanjan
University of Medical Sciences, Zanjan, Iran.

The use of targeted drug delivery systems is a growing trend in cancer treatment
to decrease the adverse effect of anti-cancer drugs. In this study, we sought to
conjugate methotrexate-human serum albumin nanoparticles (MTX-HSA NPs) with
luteinizing-hormone releasing hormone (LHRH). The LHRH was intended to target
LHRH receptors overexpressed on the several types of tumors. The expression of
LHRH receptors on the 4T1 breast cancer cells was confirmed by FITC conjugated
LHRH receptor antibody using fluorescence microscopy. Female Balb/c mice bearing
4T1 breast cancer tumor were treated with a single i.v. injection of free MTX,
non-targeted MTX-HSA NPs and LHRH targeted MTX-HSA NPs. LHRH targeted MTX-HSA
nanoparticles showed stronger anti-tumor activity in vivo. By 7 days after
treatment, average tumor volume in the LHRH targeted MTX-HSA NPs treated group
decreased to 8.67% of the initial tumor volume when the number of attached LHRH
molecules on MTX-HSA NPs was the highest, while the average tumor volume in
non-targeted MTX-HSA NPs treated mice grew rapidly and reached 250.7% of the
initial tumor volume 7 days after the treatment. LHRH targeted MTX-HSA NPs could
significantly extend the survival time of tumor bearing mice compared with the
non-targeted MTX-HSA NPs and free MTX formulations.

Copyright © 2012. Published by Elsevier B.V.

PMID: 22531853 [PubMed - as supplied by publisher]